Rare Malignancies - Day 2 - 3 March 2023
Welcome & Introduction
Decoding Treatment Options for EGFRm NSCLC
Osimertinib as Adjuvant Therapy in patients with resected EGFRm Stage IB IIIA NSCLC-Updated Results from ADAURA
Pathology of Salivary Gland Cancers
Surgery in Salivary Gland Tumors
Role of RT in Salivary Gland Tumors
Systematic Therapy in Salivary Gland Tumors
Panel Discussion
Expert Comment
Closing Remarks & Vote of Thanks